Accelmed Partners, a private equity firm focused on acquiring and investing in U.S. commercial stage, lower middle market HealthTech companies, has made two hires in its senior leadership team. Eric Tansky, former managing director in Oppenheimer & Co.’s medical technology practice, has joined the firm as general partner, and Stephen Rubin, former co-head of Proskauer’s private equity group, as partner.
“Eric and Steve are both deeply experienced and well-respected in their fields, are of high character, and, most importantly, share Accelmed’s commitment to seeking to provide strong risk-adjusted returns to investors by capturing dynamic HealthTech investment opportunities,” said Uri Geiger, founder and managing partner of Accelmed. “Having known both Eric and Steve for some time, I’ve seen first-hand their transaction expertise, strong relationships and industry insights, and can confidently say how fortunate we are to be able to leverage their collective skillsets as we build upon the successful recent close of our second fund.”
Tansky added, “Accelmed has proven itself as a strong investment and operational partner to management teams at the companies in which it invests, and I look forward to working closely with Uri and the entire team to continue driving significant value for our portfolio companies and investors in the years to come.”
Rubin commented, “I am pleased to join Accelmed at this exciting time in the industry’s evolution – when there is high demand for partnerships between innovative HealthTech companies and value-add investment partners such as Accelmed.”
In addition to Tansky and Rubin, Accelmed has also bolstered its Executives Network with the additions of Lewis Pell and Stanley Stern, executives in the fields of medical technology and investment banking, respectively. Pell and Stern will join Accelmed’s existing executives network members, all of whom have successfully built, led and sold businesses and assist Accelmed in identifying and analyzing potential investment opportunities. The expansion of Accelmed’s senior team and executives network follows the recent close of Accelmed Fund II LP at a hard cap of $400 million, and the firm’s investments in TearLab, NeuroPace and MedMinder.